Aurora Cannabis (ACB) is pleased to announce the company’s discovery of a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora’s breeding program, is set to produce powdery mildew resistant cultivars that will be explored for commercial launch this year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Aurora Cannabis expands medical cannabis pastille offerings in Australia
- Aurora Cannabis Enhances Access to Medical Cannabis in Australia
- Aurora Cannabis (ACB) Trades at a Discount Despite Record-Breaking Quarter
- Aurora Cannabis Secures Strategic $27 Million Supply Agreement with SNDL
- Aurora Cannabis announces supply agreement with SNDL